Compare Taskus Inc (TASK) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Taskus Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? Taskus Inc trades at $8.1 (market cap $750.00M), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 6.5× Taskus Inc's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, Taskus Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Taskus Inc for 35 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| TASK | TVTX | |
|---|---|---|
Market Cap | $750.00M | $4.88B |
Volume | 195,383 | 1,668,577 |
Sector | Technology | Health |
52-Week High | $14.30 | $67.52 |
52-Week Low | $4.57 | $26.79 |
Typical Hold Time | 35 Days | 0 Days |
Enterprise Value | $1.12B | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TaskUs (TASK) trades at $8.14, up 1.88% with bullish technical signals from moving averages. The company shows strong fundamentals with revenue growth to $1.18B in 2025 and net income margin expanding to 8.75%. Valuation metrics appear attractive with P/E of 7.05 and P/S of 0.62. Recent Q2 2026 earnings beat expectations with $0.33 EPS versus $0.28 expected, driven by AI services growth offsetting declines in other segments.
The outlook remains positive with analyst consensus price target of $9.33 representing 15% upside potential. Key opportunities include AI services expansion growing 26% annually, while risks involve margin compression from higher labor costs and client concentration. Institutional ownership increased with Dimensional Fund Advisors raising stake by 12.8% in Q1 2026.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Taskus Inc
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Read more on TASK →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
